Upgrades

We reiterate BUY on Metro, while revising up our TP by ~14% to Rs1,475 (60x Sep-27E pre-IndAS EPS). The change in TP is led by near-equal contribution from upward revision of estimates and earnings rollover.

Retention of clients by sacrificing margins in the near term: In the backdrop of higher tariff of 50%, Gokex management has given more impetus on client retention by providing discounts of 15-18% rather maintaining the EBIDTA margins. It has good order book outlook for Spring summer season till Q4FY26. With this strategy management expects revenues to remaining at Rs900-1000crore (after discount of 18% on additional tariff of 25%) per quarter, while consolidated EBIDTA margins...

expects ~30% growth in EU sales in the first year post-approval, translating to ~2,500 MT additional volume as per the company. Expect revenue/EBITDA to grow at 13%/85%, respectively, over FY25-27E. We value Apex at 17X P/E and recommend BUY rating with a revised target price of Rs. 284....

We expect yield compression to persist in the medium term as the company pivots toward secured lending to enhance competitiveness and attract high-value clients. Asset quality in the gold loan segment remains stable, supported by strong gold prices. However, risks in the nongold portfolioparticularly MFI, MSME, and vehicle financeremain elevated. Near-term credit cost pressures are likely to continue, though improved employee incentives may support recoveries and offset provisioning risks. As the company navigates its stabilization phase, improvements are expected to unfold gradually. Given the recent price hike and stretched...

UltraTech Cement (UTCEM) has in the recent past strengthened its market presence in the southern region through organic and inorganic expansions. The company’s grey cement capacity mix in the south region has increased to ~27% of total capacity currently from ~16% in FY23.

We attended the RP-Sanjiv Goenka Group Investor Day 2025 this week where CESC unveiled its ‘Growth Vision 2030’. At the crux, it seeks to double profits by FY30 via the levers of Distribution Company (DISCOM) capex, RE generation and solar manufacturing.

Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives....

Given the strong fundamentals and product diversification, we believe ZFCV will be a direct beneficiary in the long run owing to economic growth, a wider portfolio and government *over or under performance to benchmark index thrusts on infrastructure development. The firm is driven by higher AMT and ECAS penetration and strategic e-mobility initiatives, despite flat trailer volumes and adverse mix. Regulatory tailwinds (ESC, AIS 113, ADAS) and a robust product pipeline support future growth. EV segment momentum continues, with targeted solutions for independent bus OEMs. Hence, factoring in 14% earnings CAGR over FY25-27E. Having said that, we...

We remain constructive on 3M India after analysing its FY25 annual report. There is focus on local manufacturing. Revenues from local manufacturing have increased from 52.9% in FY14 to 59.4% in FY25.